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Abstract
Background: Mycolactone is a polyketide toxin secreted by the mycobacterium Mycobacterium ulcerans, responsible for the
extensive hypoalgesic skin lesions characteristic of patients with Buruli ulcer. A recent pre-clinical study proposed that
mycolactone may produce analgesia via activation of the angiotensin II type 2 receptor (AT2R). In contrast, AT2R antagonist
EMA401 has shown analgesic efficacy in animal models and clinical trials for neuropathic pain. We therefore investigated the
morphological and functional effects of mycolactone in cultured human and rat dorsal root ganglia (DRG) neurons and the
role of AT2R using EMA401. Primary sensory neurons were prepared from avulsed cervical human DRG and rat DRG; 24 h
after plating, neurons were incubated for 24 to 96 h with synthetic mycolactone A/B, followed by immunostaining with
antibodies to PGP9.5, Gap43, b tubulin, or Mitotracker dye staining. Acute functional effects were examined by measuring
capsaicin responses with calcium imaging in DRG neuronal cultures treated with mycolactone.
Results: Morphological effects: Mycolactone-treated cultures showed dramatically reduced numbers of surviving neurons and
non-neuronal cells, reduced Gap43 and b tubulin expression, degenerating neurites and reduced cell body diameter, com-
pared with controls. Dose-related reduction of neurite length was observed in mycolactone-treated cultures. Mitochondria
were distributed throughout the length of neurites and soma of control neurons, but clustered in the neurites and soma of
mycolactone-treated neurons. Functional effects: Mycolactone-treated human and rat DRG neurons showed dose-related
inhibition of capsaicin responses, which were reversed by calcineurin inhibitor cyclosporine and phosphodiesterase inhibitor
3-isobutyl-1-Methylxanthine, indicating involvement of cAMP/ATP reduction. The morphological and functional effects of
mycolactone were not altered by Angiotensin II or AT2R antagonist EMA401.
Conclusion: Mycolactone induces toxic effects in DRG neurons, leading to impaired nociceptor function, neurite degen-
eration, and cell death, resembling the cutaneous hypoalgesia and nerve damage in individuals with M. Ulcerans infection.
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Background
Buruli ulcer is an infectious necrotizing skin disease caused
by Mycolactone (ML), a lipid macrolide toxin secreted by
the causative bacteria Mycobacterium ulcerans, with the
third highest incidence of mycobacterial disease after
tuberculosis and leprosy. It is a neglected tropical disease
that causes signiﬁcant disﬁguration, aﬀecting mostly mal-
nourished children and fewer adults.1,2 Infected individ-
uals develop a subcutaneous painless nodule that
ulcerates, leading to extensive necrotic skin lesions with
loss of adipose and nerve tissue often extending to muscle
and bone, resulting in severe deformity. Antibiotic therapy
with Rifampicin and Streptomycin is eﬀective, but major
reconstructive surgery is often required.1,3
The cytotoxic eﬀects ofMLareknown inavariety of cell
types including epithelial cells,4,5 adipocytes,6 ﬁbro-
blasts,7,8 andmonocytes.9 Cultured ﬁbroblasts andmacro-
phage cell lines treated with ML show cell rounding,
inhibition of protein synthesis, and cell-cycle arrest in
G0/G1 leading to cell death.7 However, little information
is available regarding the molecular and cellular mechan-
isms underlying the analgesia that is typical of Buruli ulcer.
A direct eﬀect on nerves is indicated from studies of mouse
footpad inoculation with M. ulcerans, resulting in nerve
bundle invasion and damage.10 Subcutaneous injection
with the toxin ML A/B in guinea pigs caused transient
hyperaesthesia and cutaneous lesions, with subsequent
sensory deﬁcit due to nerve damage.9,11 A recent report,
however, proposed that the analgesic eﬀects of ML in
rodents may not involve nerve damage and could be
mediated by potassium-dependent hyperpolarization via
the angiotensin II (AngII) type 2 receptor (AT2R).
12
A characteristic feature of Buruli ulcer is the absence
of an inﬂammatory response, with T cell depletion in
peripheral lymph nodes and lack of a lymphocyte
homing response, involving depleted synthesis of cyto-
kines and inﬂammatory mediators,13,14 features that
are mimicked in vitro by ML. A molecular mechanism
of aberrant translocation of secreted cytokine proteins
has also been proposed to underlie the pathogenic
eﬀect of ML15 and lack of inﬂammatory hyperalgesia.
The slow growth ofM. Ulcerans, and limited availabil-
ity of its secreted toxin ML, which is comprised of two
macrolides A and B,7 led to the chemical synthesis of
ML A/B, providing a chemically well-deﬁned molecule
facilitating further studies, and which has been used in
this study.16 To investigate the mechanisms of ML-
induced analgesia, we examined the morphological eﬀects
of synthetic ML A/B on neurites and mitochondrial dis-
tribution in cultured human and rat dorsal root ganglion
neurons. As nociceptive DRG neurons are activated by a
number of noxious agents including capsaicin (the hot
ingredient of chilli peppers),17 we also determined the
functional eﬀects of ML on transient receptor potential
vanilloid subtype 1 (TRPV1) activation18 by measuring
calcium inﬂux in response to capsaicin. The potential
role of AT2R was investigated by using its endogenous
ligandAngII and selective antagonist EMA401, using pre-
viously described techniques.19
Methods
Preparation of Human DRG neurons
Cultured neuronswere prepared as previously described;19
brieﬂy, avulsed human cervical DRG (hDRG) were
obtained as a necessary part of the surgical nerve repair
procedure from three patients, with full informed consent
and approval of the Local Research Ethics Committee,
Royal National Orthopaedic Hospital, Stanmore, UK.
Tissue was enzyme-digested and mechanically dissociated
to yield a neuronal suspension, which was plated on colla-
gen and laminin-coated glass bottomed MatTek dishes
(MatTek Corp., Ashland, MA, USA) in Ham’s F12
medium containing 10% heat-inactivated fetal calf
serum, penicillin and streptomycin (100mg/mL each), the
neurotrophic factors (NTFs), nerve growth factor (100 ng/
mL), and glial cell-line derived NTF (50ng/mL). Cultures
were incubated at 37C in a humid environment containing
5% CO2/air for 48 h before calcium imaging studies.
Preparation of rat (rDRG) neurons
Bilateral DRG from all levels were harvested from 10 adult
femaleWistar rats (Charles River UKLtd,Margate, Kent,
UK) and neuronal cultures were prepared as previously
described,19 and incubated in BSF2 medium (containing
2% heat inactivated fetal calf serum, 0.1mg/mL
transferrin, 60ng/mL progesterone, 0.16mg/mL sodium
selenite, 3mg/mL bovine serum albumen (BSA), penicil-
lin/streptomycin 100mg/mL each, 16mg/mL putrescine,
10mg/mL insulin) and NTFs for 24h. Calcium imaging
studies were conducted 48h after plating.
Morphological effects
Twenty-four hours after plating, rDRG cultures were
treated with 1, 10, or 100 nmol/L ML for 24–96 h and
compared with vehicle-treated controls (0.2% ethanol)
in duplicate, followed by 4% paraformaldehyde ﬁxation
for 20min.MLdoses selectedwere in the range of previous
studies, for epithelial cells 0.1–100 ng/ml, (0.135–
135 nmol/L),4,5 and monocytes 300 pg/ml, (400 nmol/L).9
For immunostaining and morphological assessments,
neurons were permeabilized with methanol (20C,
3min), washed with PBS, immunostained with primary
antibodies to Gap43 (mouse monoclonal, 1: 200; Sigma),
or mouse monoclonal anti b-tubulin III (T8578 Sigma,
1:200), or rabbit anti PGP9.5 (1:500, Ultraclone, UK),
and visualized with donkey anti-mouse IgG (Alexa 488,
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1:200; Molecular Probes), goat anti-mouse IgG (Alexa
488, 1:200; Molecular Probes), or goat anti-rabbit IgG
(Alexa 488, 1:200; Molecular Probes), for 1 h each at
room temperature. The glass bottom cover slips were
mounted on glass slides in glycerol containing Hoechst
dye 33342 and anti-fade agent DABCO [1,4-diazobicy-
clo-(2,2,2)-octane], and sealedwith nail varnish. Tiﬀ ﬂuor-
escence images were acquired with an upright Olympus
microscope (BX43, Olympus Medical, Essex, UK) using
Cellsens software (Olympus, Japan) and wideﬁeld epi-
ﬂuorescence optics, after conﬁrming the absence of immu-
nostaining in negative controls, where the primary
antibody had been omitted. The longest neurite length
was measured from individually identiﬁable neurons in
the ML-treated and vehicle-treated groups of cultures,
using Cellsens software (Olympus, Japan), and the aver-
age is expressed as percent of control.
Live cell confocal imaging of mitochondria
Forty-eight hours after plating, neuronal cultures were
treated with 100 nmol/L ML or vehicle for 48 h, then
rinsed in HEPES buﬀered Hanks balanced salt solution
(HBSS) containing 0.1%BSA, and incubated in this solu-
tion with 50 nmol/LMitotracker Green FMdye (M-7514,
Life Technologies) for 30min at 37C. The dye was
washed oﬀ and the cells were imaged in HEPES buﬀered
HBSS on a Leica TCS SP5 II confocal microscope, using
ﬂuorescene isothiocyanate and DAPI settings for TIFF
image acquisition. A separate group of neuronal cultures
were similarly treated with 100 nmol/L ML or vehicle for
48 h, and labeled with Mitotracker Red as described
above, followed by 4% paraformaldehyde ﬁxation for
15min. Cultures were then permeabilised with methanol
and immunostained with mouse monoclonal anti b-tubu-
lin III (T8578 Sigma, 1:200), visualized with ﬂuorescene
isothiocyanate conjugated goat anti mouse secondary
antibody (1:200, Sigma). Coverslips were mounted as
described above, and confocal images were acquired.
Calcium imaging
Functional eﬀects of acute ML treatment were assessed
by measuring capsaicin responses via TRPV1 in 2 mmol/
L Fura2 AM (Molecular Probes Life Technologies,
Paisley, UK) loaded neurons, as previously described.19
Responses to paired capsaicin stimuli, with and without
ML, EMA401, or AngII were measured as a change in
the baseline 340/380 ex nm ratio before, during, and
after addition. Experiments were conducted at 37C in
a humidiﬁed environment on an inverted Nikon micro-
scope (Diaphot 300; Nikon, UK Ltd, Kingston upon
Thames, Surrey, UK), using alternate excitation at 340
and 380 nm ex/510 em wavelengths; images were
acquired every 2 s.
Lyophylized AngII was reconstituted in sterile dis-
tilled water, aliquoted, and stored at 20C. EMA401
was dissolved in HBSS containing 0.1% BSA (pH 7.4)
and stored at 4C. Synthetic ML A/B, 0.2mg/ml in
DMSO was kindly provided by Prof. Y. Kishi
(Harvard University, USA), aliquoted, and stored at
20C; fresh aliquots were thawed immediately before
use, and further diluted in ethanol to 500 ﬁnal concen-
tration. All chemicals were obtained from Sigma, Poole,
UK, unless stated otherwise. Student’s unpaired t-Test
was used to compare between groups; *p< 0.05 was con-
sidered to be statistically signiﬁcant.
Results
Effect of ML on neurites
Morphological eﬀects of ML in rDRG neurons were
apparent 24 h after treatment, when PGP9.5 immunos-
taining showed fewer surviving neurons with smaller,
degenerating neurites, compared with controls
(Figure 1(a)–(f)). ML-treated cultures showed a dramatic
loss of neurons and non-neuronal cells with surviving
cells appearing shrunken at higher doses, having reduced
cytoplasm and compact, very bright nuclei, and indica-
tive of apoptosis. The neurite outgrowth assay showed a
dose dependent decrease in neurite length after 24 h ML
treatment, compared to controls (Figure 1(g)). The aver-
age maximum neurite lengths were decreased with ML
treatment, and statistically signiﬁcant at 100 nmol/L ML
(*p< 0.05, paired t-Test); n¼ 3 experiments, total 318
neurons. Neurite loss was greater after 48 h 100 nmol/L
ML treatment (**p¼ 0.010), and was not aﬀected by the
presence of 100 nmol/L EMA401 (**p¼ 0.007)
(Figure 1(h)); n¼ 3 experiments, total 302 neurons.
Effect of ML on Gap43
Gap43 immunostaning was uniformly distributed in the
cell bodies and neurites of control neurons (Figure 2(a),
(b)) but was very bright in the surviving neuronal cell
bodies and very faint in the degenerating neurites, in neu-
rons treated withML for 96 h (Figure 2(c), (d)), indicating
accumulation in the cell body and reduced axonal trans-
port. Similarly, non-neuronal cells, predominantly
Schwann cells and ﬁbroblasts, showed prominent nuclei
surrounded by substantial cytoplasm (Figure 2(e)).
ML-treated cultures had shrunken cells with little or no
cytoplasm and small very bright nuclei (Figure 2(f)).
Effect of ML on mitochondria and  tubulin
Confocal imaging showed uniformly distributed b
tubulin in the soma and neurites of control neurons co-
localized with evenly dispersed Mitotracker red-stained
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mitochondria (Figure 3(a)–(d)). ML-treated neurons
showed greatly reduced b tubulin in the soma and com-
plete loss of staining in the neurites, with clumped mito-
chondria concentrated in the cell bodies and neurites of
ML-treated neurons and brightly stained nuclei
(Figure 3(e)–(h)). This was conﬁrmed with live cell
confocal imaging using the Mitotracker Green FM
dye, which also showed uniformly dispersed mitochon-
dria along the entire length of neurites and cell body in
control neurons (Figure 3(i), (j)), while ML treatment
resulted in clumped mitochondria that were accumulated
in the cell bodies (Figure 3(k)).
Figure 1. Loss of neurites in ML-treated rDRG neurons. PGP9.5 immunofluorescent neurons in control DRG cultures showing dense
clusters (a) and a single neuron with profuse neurite outgrowth (b); Dose-related loss of neurites was observed after 24 h treatment with
1 nmol/L ML (c); 10 nmol/L ML (d); and 100 nmol/L ML (e); Co-incubation with the AT2R antagonist EMA401 did not affect ML-induced
neurite degeneration (100 nmol/L each) (f); Graphs showing summary of neurite lengths after 24 h ML treatment (*p< 0.05, paired t-test)
(g); Neurite lengths were significantly reduced after 48-h treatment with 100 nmol/L ML (**p¼ 0.010), and similar to neurons treated with
combined EMA401 and ML (100 nmol/L each, **p¼ 0.007) (h). Bar in (a)¼ 50m (same magnification in b–h).
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Effect of ML on capsaicin responses in human
DRG cultured neurons
Acute functional eﬀects of ML were apparent in rDRG
and hDRG neurons, 10min after application, as dose-
related inhibition of capsaicin responses. In hDRG
neurons, incubation with high dose ML (1.3 mmol/L)
completely inhibited capsaicin responses, but was
reversed following a 30-min rest period after washout
(Figure 4(a)–(d)). Dose-related inhibition of capsaicin
responses was observed (Figure 4(e)). Percent inhib-
ition s.e.m. with 260 nmol/L (equivalent to 200 ng/
ml) ML was 69 12%, n¼ 7 neurons, **p¼ 0.003; and
with 1.3mmol/L (1 mg/ml) ML was 98.3 0.7%, n¼ 3
neurons, **p¼ 0.004. Tachyphylaxis to repeat capsaicin
challenge alone, as control, was similar to previous
studies, 19.3 5.5% (eight neurons).
Effect of ML on capsaicin responses in
rDRG-cultured neurons
In rDRG neurons, capsaicin responses were blocked in
the presence of 300 nmol/L ML (Figure 5(a), (b)); this
eﬀect was reversible following a 30-min rest period after
washout, when capsaicin sensitivity was restored
(Figure 5(c)). Dose-related inhibition of capsaicin
responses was observed in the presence of ML
(Figure 5(d)); n¼ 3 experiments, (% inhibition s.e.m):
0 nmol/L ML, 18.9 4.4, 28 neurons), 3 nmol/L ML,
(48.1 7.2, 8 neurons), 10 nmol/L ML, (62.1 6.6,
Figure 2. Gap43 immunofluorescence was localized in the cell bodies and long profuse neurites in individual control rDRG neurons (a,
b). Surviving neurons after 100 nmol/L ML treatment for 96 h showed shrunken cell bodies with disintegrated neurites (c, d). Non-neuronal
cells comprising Schwann cells and fibroblasts in control cultures showed well-spread viable cells with distinct cytoplasm and nuclei (e). ML
treatment resulted in shrunken neurons (arrows) and non-neuronal cells (arrowheads), with bright condensed nuclei typical of apoptosis
(f). Bar in (a) and (c)¼20m, in (b) and (d)¼50m, and in (e) and (f)¼100m.
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14 neurons), 30 nmol/L ML, (69.6 4.9, 20 neurons),
100 nmol/L ML, (85.6 5.1, 26 neurons), 300 nmol/L
ML, (96.2 1.1, 21 neurons), IC50¼ 10 nmol/L. The
inhibition of capsaicin response by 300 nmol/L ML was
not aﬀected by 100 nM AngII (96.9 1.4, 7 neurons,
p> 0.05). Similarly, capsaicin inhibition by 10 nmol/L
ML was not aﬀected by the presence of 100 nmol/L
EMA401 (68.8 10.4, 5 neurons, p> 0.05). Application
of 100 nmol/L or 1 mmol/L ML alone did not stimulate
calcium inﬂux (data not shown). Inhibition of capsaicin
response by 100 nmol/L ML (85.6 5.1, 26 neurons) was
abolished in the presence of 10 mmol/L cyclosporine (cal-
cineurin inhibitor, 25.3 3, 21 neurons), and 66 mmol/L
IBMX (3-isobutyl-1-Methylxanthine; phosphodiesterase
inhibitor, 15.5 3.9, 27 neurons) (Figure 5(e)).
Discussion
This study shows that ML treatment of DRG cell cul-
tures had extensive morphological and functional eﬀects,
targeting both neurons and non-neuronal cells. These
eﬀects were seen across all neuronal cell sizes, indicating
the absence of a selective eﬀect on any particular sub-
population. We observed neurite degeneration and cell
death, reduced Gap43 and loss of b tubulin, mitochon-
drial clumping, and TRPV1 inhibition in ML-treated
DRG neurons. These ﬁndings are likely to contribute
to the lack of pain in Buruli ulcer infection.
ML secreted by Mycobacterium ulcerans is known to
cause the extensive skin lesions typical of Buruli ulcer,
which despite their severity are hypoalgesic. Previous
Figure 3. ML effect on rDRG neurons. Low power confocal images of control neurons (a–d) showing uniform distribution of b tubulin in
the cell body and neurites (a), Hoechst dye stained nuclei (b), uniformly dispersed Mitotracker red labeled mitochondria (c) and the
merged image with overlapping b tubulin and mitochondria (yellow, d). ML-treated neuron (100 nmol/L for 48 h) (e–h), showing loss of
neurites and b tubulin (e), prominent nucleus (f), clumped Mitotracker Red positive mitochondria (g), and merged image (h). Live cell
Mitotracker green labeling of mitochondria which are dispersed throughout the cell body (arrow) and neurites in a control neuron (i), and
high power confocal images of the same neuron (j). In a ML-treated neuron, the Mitotracker label shows clumping of mitochondria
restricted to the cell body, and loss of neurites (k). Bar in (a)¼25 microns (a–h same magnification).
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Figure 4. Acute effects of ML on capsaicin responses in hDRG neurons. Brightfield image of a human DRG neuron (a), showing increased
fura 2 ratio in response to 200 nM capsaicin and the corresponding trace (b), followed by complete inhibition of 1mol/L capsaicin response
in the presence of 1.3mol/L ML (c). The acute inhibitory effect of ML was reversible following washout, and the capsaicin response was
restored (d). Graph showing percent inhibition of responses to 1M capsaicin dose dependently inhibited in the presence of 260 nmol/L ML
(**p¼ 0.003) and 1.3mol/L ML**p¼ 0.004 (e).
Figure 5. Acute effects of ML on capsaicin responses in rDRG neurons. Trace showing increased fura2 ratio in response to 200 nM
capsaicin (a). Near complete inhibition was observed in the presence of ML 300 nmol/L (b). The acute inhibitory effect of ML was reversed
following a 30-min rest period after washout, and robust responses to capsaicin and ionomycin were observed (c). Graph showing ML
dose-related inhibition of capsaicin responses following acute incubation with ML (d). Graph showing inhibition of capsaicin responses by
100 nmol/L ML, which were abolished in the presence of cyclosporine and IBMX (e). *p< 0.05, **p< 0.01, ***p< 0.001.
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studies in guinea pigs have shown that ML itself is suf-
ﬁcient to cause the extensive lesions, with accompanying
immunosuppression by a mechanism of apoptotic cell
death.7,9,20 These eﬀects have also been described in
ﬁbroblasts, macrophages, adipocytes, and muscle and
are similar to our observations. The massively reduced
numbers of DRG neurons and non-neuronal cells, with
the remaining cells having shrunken cell bodies and
bright condensed nuclei, are suggestive of apoptosis.
While we have not quantiﬁed neuronal mortality in
our study, examination of morphological eﬀects
showed up to 95% cell loss at the highest concentration
of ML used. These ﬁndings are in keeping with the histo-
pathological observations in necrotic lesions resulting
from ML injection in guinea pig skin and from infected
patients, where destruction of the subcutaneous adipose
tissue leads to collapse of the epidermis and formation of
a characteristic ulcer with undermined edges and nerve
damage.21–23 This would indicate a common mechanism
by which ML targets a variety of cell types, as observed
in the histopathology of tissues from infected individ-
uals. Indeed, the potent toxicity proﬁle of ML has
prompted its development for therapeutic use as an
anti-tumor agent.24,25
We observed dense clusters of PGP 9.5 positive
neurons with profuse neurite outgrowth in control cul-
tures, while ML-treated cultures showed vastly reduced
numbers of neurons with shortened, faintly positive,
degenerating neurites. These features are similar to
those previously described with the chemotherapy drug
oxaliplatin in DRG neuronal cultures, due to a toxic
eﬀect presenting as dying back of neurites.26 Co-treat-
ment with the AT2R antagonist EMA401 did not aﬀect
ML-mediated degenerative eﬀects, indicating lack of
involvement of the AT2R in ML-mediated neurotoxicity.
Similarly, while Gap43 was expressed in the neurites and
cell bodies of control neurons, ML-treated cultures
showed a dramatic reduction in the number of surviving
neurons, with Gap43 immunostaining restricted to the
cell bodies of surviving neurons, accompanied by degen-
erating neurites. Gap43 is a marker of regenerating neu-
rons, and its reduced expression indicates impaired
regeneration and viability. The reduced expression of
PGP9.5, Gap43, and b tubulin combined with neurite
loss is consistent with reports of impaired protein syn-
thesis after ML treatment.15 These are the ﬁrst such
observations of ML eﬀects in DRG neurons and are
similar to reports of cell rounding and loss described in
other cell types treated with ML.
Our ﬁndings in DRG cultures are in accord with
reports of nerve damage underlying the hypoalgesia
characteristic of Buruli ulcer in preclinical and clinical
studies.10,11 A clinicopathological study of 45 patients
with Buruli ulcer conﬁrmed that peripheral nerves are
targeted, with severe degeneration and disruption of
nerve bundles, along with the presence of apoptotic mar-
kers.27 ML toxin occurs in variable but measurable
quantities in the necrotic Buruli ulcer lesions from
infected patients (median 439 ng/ml)28 and is found to
accumulate in the peripheral blood and internal organs
especially spleen of subcutaneously ML-injected mice,29
indicating its ubiquitous distribution in the body. This is
likely to result in altered nerve function and nerve
damage, supported by the observation of degenerating
neurites in our study. In accord, animal studies have
shown that ML can damage nerves directly.30
In our study, confocal imaging of b-tubulin immunos-
taining combined with Mitotracker Red FM dye showed
uniformly distributed speckled staining indicating indi-
vidual mitochondria and b tubulin along the entire
length of the neurites and in the cell body, in agreement
with other studies.31,32 ML-treated neurons on the other
hand, showed near complete loss of b tubulin and axon
degeneration, combined with clumped mitochondria
accumulated in the cell body. Live cell confocal imaging
with Mitotracker Green conﬁrmed the loss of neurites
and clumping of mitochondria in the cell bodies of
ML-treated neurons. These observations may be related
to the eﬀect of increased mitochondrial membrane
depolarization reported in keratinocyte cell lines treated
with ML.4 Neuronal mitochondria are normally
involved in retrograde and anterograde movement, and
mitochondrial clustering in the cell body is associated
with impaired traﬃcking of mitochondria to the distal
axons, due to an imbalance in transport. Bidirectional
transport of mitochondria normally occurs within
actively growing axons,31,32 via motor proteins along
microtubule tracks,32 and are withdrawn from non-
growing axons and areas of low metabolic demand.31
Mitochondrial traﬃcking, as with other organelles, is
subject to the phosphorylation status of microtubule-
associated proteins, depending on a regulated balance
between phosphatases and kinases.33,34 As microtubule-
dependent transport of mitochondria is a critical factor
for maintaining local ATP generation in the distal pro-
cesses of neurons, particularly relevant due to the exten-
sive lengths of peripheral nerve ﬁbers, accumulation of
mitochondria in the cell body indicates disruption of
these processes, potentially leading to impaired neuronal
function. Mitochondrial clustering in the neuronal cell
body is a characteristic feature of neurodegenerative dis-
orders, associated with increased microtubule associated
protein tau expression and its hyperphosphorylation, as
seen in Alzheimer’s disease.35 Proteomic studies have pre-
viously shown reduction of regulators of microﬁlaments,
microtubules, and collagen in ML-treated ﬁbroblasts.36
Thus, the loss of b tubulin, axon degeneration, and mito-
chondrial clustering following ML treatment in our
study provides a morphological basis for impaired neur-
onal function.
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As hypoalgesia is a characteristic feature of Buruli
ulcer, we examined the functional eﬀects of ML on cap-
saicin-mediated calcium inﬂux via the TRPV1 receptor.
The TRPV1 receptor is a Ca2þ permeable, non-selective
cation channel that is expressed in the plasma membrane
of sensory neurons and is activated by noxious signals
including temperatures above 42C, protons (low pH),
inﬂammatory mediators, and plant-derived chemicals
such as capsaicin, the pungent ingredient of chilli pep-
pers, to mediate the sensation of pain via calcium
inﬂux.37 One of the mechanisms regulating TRPV1 sen-
sitivity involves cAMP-dependent PKA,38,39 and the
reduced expression of TRPV1 in patients with sensory
neuropathy is correlated with reduced nociceptor func-
tion.40 In vitro studies have shown the importance of
TRPV1 activity in ﬁlopodial extension and maintenance
of neurites via the enhanced expression of tubulin and
myosin IIA and IIIA motors.41 Our results showed that
capsaicin responses in human DRG neurons were dose
dependently inhibited in the presence of ML, an acute
reversible eﬀect, as capsaicin sensitivity was restored fol-
lowing immediate washout. Rat DRG neurons also
showed dose dependent inhibition of capsaicin responses
by ML at similar doses to those used in previous stu-
dies.4,12 The functional eﬀects of ML preceded the mor-
phological eﬀects, which were apparent only after several
hours in culture. Mechanistic insight can be derived from
the abolition of ML-mediated TRPV1 inhibition by the
protein phosphatase 2B (calcineurin) inhibitor cyclo-
sporine and the phosphodiesterase inhibitor IBMX:
both result in increased cAMP that may rescue TRPV1
function by phosphorylation and sensitization.39,42,43 It
should be noted that these are acute prophylactic eﬀects,
their ability to reverse inhibition, and long-term actions
deserve further investigation. Our study also suggests
that rDRG neurons may be more sensitive to the eﬀects
of ML compared with human neurons, as the presence of
100 nmol/L ML resulted in more than 80% inhibition in
rat neurons, while inhibition was observed in human
neurons at higher concentrations (200 ng/ml), although
the eventual eﬀects were similar.
It is not clear to what extent the AT2R is speciﬁcally
targeted by ML in vivo, as the ML concentrations
reported in one study to stimulate AT2 receptors were
very high, in the 3 mg/ml range (c. 4 mmol/L),12 whereas
the ML levels required to cause hyperpolarization of rat
hippocampal neurons in vitro12 and found in tissues after
infection, were one to two orders of magnitude lower.
This study also reported similar binding aﬃnity of ML at
micromolar levels to the AT1R and AT2R, but ML only
activated AT2R, and that ML hyperpolarization of
rodent hippocampal cultured neurons was inhibited by
the AT2R antagonist PD123,319.
12 Our ﬁndings, and
those of others, indicate diminished activity in DRG
nociceptors by AT2R antagonists across the range of
in vitro and animal pain models and clinical trials of
neuropathic pain (our unpublished observations in
patients with chemotherapy-induced painful neur-
opathy).44–48 EMA401 inhibited AngII and capsaicin
responses in rat- and human-cultured DRG neurons
with IC50 of 10 nmol/L.
44 This contrast could reﬂect dif-
ferences in AT2R signaling between CNS (hippocampal)
and DRG neurons. In our present study, the AT2R
agonist AngII did not aﬀect ML-mediated inhibition of
capsaicin responses in DRG neurons. As treatment of
DRG neurons for 48 h with combined EMA401 and
ML did not prevent cell loss or neurite degeneration,
and EMA401 did not prevent acute functional eﬀects
of ML, it is unlikely that AT2R antagonism would pre-
vent ML-induced pathology in primary sensory neurons.
The eﬀects of ML in diﬀerent cell types may underlie
the lack of inﬂammatory pain in Buruli ulcer. Danser
and Anand,49 and others, have suggested that the
absence of inﬂammatory pain in Buruli ulcer results
from ML eﬀects on both inﬂammatory cells and cutane-
ous nociceptors. ML inhibits protein translocation into
the endoplasmic reticulum resulting in the deﬁcit of cyto-
kines.15 Such an eﬀect would explain the lack of inﬂam-
mation, secretion of inﬂammatory cytokines, and,
thereby, the lack of inﬂammatory pain sensation.
TRPV1 inhibition observed in the presence of ML may
contribute to the hypoalgesia associated with Buruli
ulcer prior to nerve damage, resembling the cutaneous
hypoalgesia and loss of nociceptor terminals in M.
Leprae infected individuals.50 The studies collectively
point to ML-mediated energy depletion and toxicity by
a common mechanism in a variety of cell types, targeting
which may provide a strategy for novel treatments.
Conclusion
ML treatment results in profound morphological and
functional eﬀects in human and rDRG neurons, which
are likely to underlie the hypoalgesia characteristic of
Buruli ulcer.
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